Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Roche achieved a sales growth of 7% (3% in CHF ... significant and clinically meaningful two years after treatment with Elevidys, compared to a pre-specified propensity-weighted untreated external ...

The result comes a few months after the only FDA-approved gene therapy for DMD – Roche/Sarepta’s Elevidys (delandistrogene moxeparvovec) – failed to meet its primary objective in a phase 3 ...

The importance of Pfizer’s candidate has been heightened in the minds of the DMD community after the only FDA-approved gene therapy for DMD, Roche/Sarepta’s Elevidys (delandistrogene ...

Their advice comes from personal experience. After entering into many tough conversations about money among themselves, friends and others, they buckled down and paid off $200,000 in debt, learned ...

Check Out Our Latest Stock Analysis on Sarepta Therapeutics Sarepta Therapeutics Stock Down 0.6 % Shares of NASDAQ:SRPT opened at $113.72 on Thursday. Sarepta Therapeutics has a 1 year low of $102 ...

aMedical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil bGrupo de Pesquisa Clínica em Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil ...

Two vaccines (Arexvy and Abrysvo) for prevention of RSV disease.

When you arrive at this page, you should enter the username and password login details provided by Worldpay in the email from shopper@worldpay.com: On this page, you will be able to cancel your ...